Safety Profile of the Respiratory Fluoroquinolone Moxifloxacin
- 1 January 2009
- journal article
- research article
- Published by Springer Nature in Drug Safety
- Vol. 32 (5) , 359-378
- https://doi.org/10.2165/00002018-200932050-00001
Abstract
Moxifloxacin, a fluoroquinolone with potent activity against respiratory pathogens, is approved and considered as an alternative to β-lactams and macrolides for the treatment of acute bacterial...Keywords
This publication has 153 references indexed in Scilit:
- Coexposure of Mice to Trovafloxacin and Lipopolysaccharide, a Model of Idiosyncratic Hepatotoxicity, Results in a Unique Gene Expression Profile and Interferon Gamma–Dependent Liver InjuryToxicological Sciences, 2008
- Cellular basis of drug‐induced torsades de pointesBritish Journal of Pharmacology, 2008
- Prevalence, Characteristics, and Molecular Epidemiology of Macrolide and Fluoroquinolone Resistance in Clinical Isolates of Streptococcus pneumoniae at Five Tertiary-Care Hospitals in KoreaAntimicrobial Agents and Chemotherapy, 2007
- Molecular Characterization of Increasing Fluoroquinolone Resistance in Streptococcus pneumoniae Isolates in Canada, 1997 to 2005Antimicrobial Agents and Chemotherapy, 2007
- Are Broad-Spectrum Fluoroquinolones More Likely To Cause Clostridium difficile -Associated Disease?Antimicrobial Agents and Chemotherapy, 2006
- Guide to Selection of Fluoroquinolones in Patients with Lower Respiratory Tract InfectionsDrugs, 2005
- Drug-Induced Prolongation of the QT IntervalNew England Journal of Medicine, 2004
- QT Prolongation with Antimicrobial AgentsDrugs, 2004
- MoxifloxacinDrugs, 2000
- Comparative Tolerability of the Newer Fluoroquinolone AntibacterialsDrug Safety, 1999